arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

CORCEPT THERAPEUTICS INC

CORT
$71.62 ▼ -7.68 (-9.68%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
78 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
74
Health
Good
Bullish
auto_awesome

Analytical Summary

CORCEPT THERAPEUTICS INC shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $7.6B
Dividend Yield —
Revenue Growth 64.0% ↗
Op. Margin 33.7% ↗
ROIC 14.5% ↗
FCF / Share $1.33 ↗
Trailing P/E 61.2x
Price / Book 9.2x
FCF Yield 1.9%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

78-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$340.47M
↑ +64.0% —
Net Income Profit after all expenses
$-31.76M
— 0.0% —
Operating Margin Operating profit as % of sales
33.7%
↑ +109.0% 45th
FCF / Share Free cash flow per share
$1.33
↑ +153.4% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↓
65
Returns ↓
81
Cash Quality →
79

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 27 years · 78 quarters